Platform Technology Overview

Our Mission is to create a novel class of therapeutics for the treatment of cancer and infectious disease, as well as other aberrant health conditions.


Pure MHC, LLC is a platform technology company with expertise in disease-specific target identification and validation, as well as immunotherapeutic drug development for cancer, infectious and autoimmune diseases, and allergy. Pure MHC identifies and leverages the same disease targets for drug discovery that the immune system naturally uses to identify foreign or aberrant protein targets in cancerous, infected, or unhealthy cells. The intrinsic value of this technology is that it provides access to every protein that is either synthesized or degraded inside any particular cell, including proteins that are not expressed on the cell surface. Using proprietary technology, Pure MHC consistently identifies previously unidentified disease targets as well as validates “Usual Suspect” targets.

The major histocompatibility complex (MHC), known as HLA in humans, is a surface expressed, transmembrane protein that presents peptide ligands for T lymphocyte recognition. Class I HLA molecules are found on all nucleated cells of the body, and they alert the immune system of pathogen-infected and cancerous cells in order to trigger destruction of the diseased cell by cytotoxic T lymphocytes. Class II HLA molecules are expressed primarily on professional antigen presenting cells (B cells, macrophages, and dendritic cells), but they can be expressed on cells in the periphery under conditions of cell stress. Unlike the intracellular spaces surveyed by class I molecules, the class II HLA molecules are responsible for surveying extracellular spaces for threats such as bacterial infection, and in turn stimulate a response appropriate (antibodies, activated macrophages, etc.) for the extracellular threat.

Soluble HLA (sHLA) is Pure MHC’s key enabling technology that allows for the expression of a pure source of HLA in a diseased cell of choice. Using sensitive mass spectroscopy techniques referred to as Deep Ligand Sequencing, Pure MHC compares thousands of peptides recovered from HLA complexes extracted from cancer, infected, and normal cells and then determines with high confidence which peptides are unique (and therefore represent novel disease targets) to the affected cell line or primary tissue. This analysis is undertaken without bias toward or against any protein or peptide (which Pure MHC terms “Usual Suspects”) previously known or suggested to be associated with the disease state under investigation.

Biomarkers discovered by Pure MHC represent nature’s own means of marking diseased cells for elimination, and Pure MHC has developed a unique class of monoclonal antibodies that are specific for the biomarkers that we discover and validate. These highly specific monoclonal antibodies mimic the immune system’s recognition mechanisms, and the provision of these monoclonal reagents compliments our discovery of disease-specific biomarkers. Moreover, Pure MHC’s monoclonal antibodies, referred to as T Cell Receptor mimics (TCRm), can readily be optimized to treat disease or for use in diagnostics, as well as for other pre-clinical development assays.